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Abstract 34 
Objective Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability in 35 
the elderly. Of all the joints, genetic predisposition is strongest for OA of the hand, however only few 36 
genetic risk loci for hand OA have been identified. Our aim was to identify novel genes associated with 37 
hand OA  and examine the underlying mechanism.  38 
Methods  We performed a genome-wide association study of a quantitative measure of hand OA in 39 
12,784 individuals (discovery:8,743, replication:4,011). Genome-wide significant signals were followed 40 
up by analysing gene and allele specific expression in a RNA-sequencing dataset (n=96) of human 41 
articular cartilage 42 
Results  We found two significantly associated loci in the discovery set: at chr12 (P=3.5 × 10-10) near the 43 
MGP gene and at chr12 (P=6.1 x 10-9)near the CCDC91 gene. The DNA variant near the MGP-gene was 44 
validated in three additional studies, which resulted in a highly significant association between the MGP-45 
variant and hand OA (rs4764133, Betameta=0.83,  Pmeta=1.8*10-15). This variant is high linkage 46 
disequilibrium with a coding variant in Matrix Gla-Protein (MGP), a vitamin K-dependent inhibitor of 47 
cartilage calcification. Using RNA-sequencing data from human primary cartilage tissue (n=96), we 48 
observed that the hand OA MGP-risk allele was significantly lower expressed compared to the reference 49 
allele (40.7%, P<5*10-16). 50 
Conclusions Our results indicate that the association between the MGP-variant and increased risk for 51 
hand OA is caused by a lower expression of MGP, which may increase the burden of hand OA by 52 
decreased inhibition of cartilage calcification. 53 
 54 
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Introduction 57 
Osteoarthritis (OA) is the most frequent joint disorder worldwide. An estimated 22% of the adult 58 
population has a joint affected by OA and this incidence increases to 49% in individuals over 65 years of 59 
age[1]. All synovial joints can be affected by OA, with hand OA as one of the most common forms of OA. 60 
Hand OA is characterized by osteophyte formation, bony enlargements of finger joints and cartilage 61 
degradation in the joints. One of the factors contributing to cartilage degradation is the increase of 62 
calcified cartilage in the joint[2,3]. In addition, hand OA is related to the occurrence of OA at other sites, 63 
most notably with knee OA[4,5]. Patients affected by hand OA suffer from pain and disability, impacting 64 
their quality of life. OA is a leading cause of chronic disability[6], yet currently no effective therapeutic 65 
treatments against osteoarthritis are known. It is therefore imperative to dissect the underlying 66 
mechanism of disease aetiology as this may enhance effective and targeted drug development.  67 
OA has a strong genetic component. Depending on the joint affected, the heritability of OA is 68 
estimated in the range of 40-60%[7,8], with hand OA having the largest heritability, i.e. ~60%[9],[10]. 69 
Therefore, in recent years, several large-scale genetic studies have been performed to identify the 70 
underlying genes and pathways leading to OA. Multiple significant associated loci for OA of the hip and 71 
knee have been identified through genome-wide association studies (GWAS)[11–18]. However, thus far, 72 
only one report has described a robust association with OA of the hand[19]. In this previous report, 73 
common variants in the ALDH1A2 and rare variants in chromosome 1p31 were genome-wide 74 
significantly associated with hand OA using a discovery cohort of 837 cases and 77,325 controls.  75 
In this study, we aimed to identify novel genes and pathways involved in the aetiology of OA of 76 
the hand by performing a large-scale GWAS. We used a semi- quantitative measure for OA of the hand 77 
in order to increase statistical power. We gathered a large sample size of 12,754 individuals for analysis., 78 
by combining data from three studies in the discovery phase and an additional three cohorts for 79 
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replication. Next, we conducted functional follow-up of our top finding to investigate the underlying 80 
mechanism. 81 
 82 
METHODS 83 
Discovery GWAS, replication and meta-analysis  84 
For a detailed description on the GWAS methods, participating studies, quality control procedures for 85 
genotyping and imputation, see supplementary text S1 and Table S1. 86 
Detailed phenotype description of KL sum-score 87 
We have used a  semi-quantitative bilateral measure of osteoarthritis of the hand based on the radiographic 88 
Kellgren and Lawrence score (KL-score)[20]. Using radiographs of both hands, the KL-score was determined for 89 
each joint in the hand. Using these KL-scores we defined the KLsum-score: the total KL-score, the sum, of the 90 
following hand joints for both hands (left and right): all Distal Interphalangeal (DIP) joints, all Proximial 91 
Interphalangeal (PIP) joints, all Metacarpophalangeal (MCP) joints , the Interphalangeal (IP) joint and the first 92 
Carpometacarpal (CMC1) joint. Which gives the sum of 15 joints on each hand, and in total 30 joints for both hands 93 
together, resulting in a minimum score of 0 and a maximum score of 120. The Leiden Studies cohort no Kellgren-94 
Lawrence scoring was done of the MCP joints, resulting in a KLsum-score of maximum 88. Individuals lacking KL-95 
grading for both or one hands and individuals with missing age or gender information were excluded from all 96 
analyses in all cohorts. As the KL-sum score has a skewed distribution the top finding of the meta-analysis was 97 
repeated in the discovery cohorts using a Poisson regression.  98 
 99 
Visualization of the associated loci and the regulatory landscape  100 
For the top GWAS associated SNP, the LD region (r2>0.8 ) was determined using the 1000G Phase-1 101 
population using the HaploReg V3 tool[21]. Using the ROADMAP generated reference epigenomes we 102 
determined if any of the variants in high LD were located in potential gene regulatory regions in primary 103 
osteoblasts (generated by ENCODE) and bone marrow derived chondrocytes (ROADMAP).  [22,23].. The 104 
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18-state chromatin reference epigenomes were downloaded from the ROADMAP epigenomes data 105 
portal[23]. SNPs and regulatory annotations were visualized busing the UCSC genome-browser on 106 
GRCh37/hg19[24]. For each variant it was also determined if the alternative allele would disrupt a 107 
protein binding motif, this was done using the HaploReg V3 tool[21]. 108 
 109 
RNA-sequencing data  110 
Post RNA isolation (Qiagen RNeasy Mini Kit, RIN>7) of 40 knee (15 paired preserved (P) and OA lesioned 111 
(OAL), 7 P only, 3 OAL only) and 28 hip (6 paired P and OAL, 14 P only, 2 OAL only) cartilage samples 112 
(Supplementary Table S2), paired-end 2x100bp RNA library sequencing (Illumina TruSeq RNA-Library 113 
Prep Kit, Illumina HiSeq2000) resulted in an average of 10 million fragments per sample. Reads were 114 
aligned using GSNAP against GRCh37/hg19, in which SNPs from the Genome of the Netherlands 115 
consortium withMAF>1% were masked to prevent alignment bias. Number of fragments per gene were 116 
used to assess quantile-adjusted conditional maximum likelihood (qCML) (edgeR, R-117 
package).Subsequently, differential gene expression analysis was performed pairwise between P and 118 
OAL samples for which we had RNA of both (n=21). ASE was assessed using SNVMix2[25] with default 119 
settings(min coverage=25, 10 reads per allele). The extent of allele specific expression (ASE) was defined 120 
as the fraction of risk allele among all counts at the respective location. Meta-analysis was done only 121 
across P samples or OAL when no P counterpart sample was present.  P-values were calculated using 122 
canonical binominal test (metagen R-package). 123 
 124 
TaqMan assay  125 
Conventional TaqMan genotyping was performed on both genomic-DNA (gDNA), articular cartilage 126 
and Subchondral bone cDNA. An allele-specific custom TaqMan assay for rs1800801 (Thermo Fisher 127 
Scientific) was used to quantify the allele ratio in cDNA samples and were normalized against the 128 
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gDNA ratio, which was used as an 1:1 allele ratio reference. Each sample has been measured in four 129 
(cartilage) or eight (subchondral bone) times, while calculations and statistics were performed as 130 
described previously[19,26]. Cartilage samples which yielded fewer than four measurements (N=2) 131 
were discarded prior to further analyses. All subchondral bone samples were assessed by eight 132 
technical replicates.  133 
 134 
 135 
RESULTS 136 
GWAS of KLsum-score 137 
We conducted a genome-wide association study (GWAS) of a semi-quantitative measure of hand OA, a 138 
bilateral summed score of Kellgren- and Lawrence scores[20], that grades radiographic OA severity, 139 
across all hand joints (KLsum-score, range of 0 to 120). The discovery set consisted of three Rotterdam 140 
Study cohorts (RSI, RSII and, RSIII) and included 8,743 participants with KLsum-scores. Replication was 141 
done in another 4,011 individuals from three different cohorts; Leiden studies(LS), Framingham heart 142 
study(FHS), and Twins-UK (TUK). General characteristics of the discovery cohorts and replication cohorts 143 
can be found in Supplementary Table S3 and in Supplementary Text S1.  144 
 The discovery analysis yielded two novel independent genome-wide significant loci (P≤5*10-8) 145 
on chromosome 12, an intergenic region between MGP and ERP27 and an intronic region in CCDC91. We 146 
also identified seven other novel loci with suggestive significance (P<5*10-6) (Figure 1). In total, nine loci 147 
were selected for replication in 4,011 individuals from three different cohorts (LS, FHS, and TUK). Using a 148 
Bonferroni corrected P-value<5.56*10-3, we significantly replicated one of nine loci, rs4764133 149 
(Betameta=0.83, SEmeta=0.10, P-valuereplication=3.4*10-07, P-valuemeta=1.8*10-15) with the same direction of 150 
effect as identified in the discovery analysis (Table 1, and Supplementary Figure S1 Forrest plot). This 151 
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locus maintained genome-wide significance and another locus near ENPP3 reached near genome-wide 152 
significance (chr6:132063842:D, Betameta=0.58, SEmeta=0.11, P-valuemeta=3.8*10-7) in the combined 153 
discovery and replication joint meta-analysis (Table 1). Since the KLsum-score has a skewed distribution 154 
the top hit was also re-analysed in the discovery set using a Poisson regression (rs4764133, 155 
Betapoisson=0.12, SEpoisson=0.02, P-valuepoisson=1.98*10-11).  156 
Our top replicated and genome-wide significant finding, rs4764133 [T] (Pmeta=1.80*10-15, 157 
Beta=0.83, MAF=0.39) is located in a non-coding intergenic region between MGP (Matrix Gla-protein) 158 
and ERP27 (Endoplasmic Reticulum Protein 27).  However, variants in high linkage disequilibrium (LD) 159 
with rs4764133 (r2≥0.8) span a ~80Kb region encompassing multiple genes, including MGP and an open-160 
reading frame C12orf60 (Figure 2A). Moreover, several of these variants are located in an mRNA 161 
transcript, including a nonsynonymous variant in MGP, and variants in 3’ and 5’UTR of MGP and 162 
C12orf60 (Table 2, Figure 2B). The nonsynonymous variant in MGP, rs4236, is predicted to be non-163 
damaging (STIFT=1, tolerated; PolyPhen=0, benign) causing a threonine to alanine amino acid 164 
substitution. Two variants  are located in predicted active promoter region of MGP (rs1800801) and 165 
C12orf60 (rs9668569) in chondrogenic cells and primary osteoblasts (Table 2).  166 
Next, we investigated the association of rs4764133 with bilateral severe hand OA and bilateral 167 
finger OA using the discovery set (RS-I, RS-II and RS-III). We found a strong association with finger OA (P-168 
value=3.09*10-08, OR=1.25) and nominal significant association with severe hand OA (p-value=2.80*10-169 
2, OR=1.36), which has a low frequency in the population (Table S4), we also see a nominal significant 170 
association with cartilage thickness in the hip joint (minimal joint space width. mJSW). To see if 171 
rs4764133 also confers risk for other forms of osteoarthritis, i.e. osteoarthritis of the hip and knee, we 172 
used the GWAS summary data of the treat the treat OA consortium[27] and the recently published 173 
mJSW meta-analysis[18]. No association was found between rs4764133 and hip or knee OA (Table S4). 174 
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However, we did find a nominal significant association between rs rs1049897 (r2= 0.98 with 175 
rs4764133)(P-value=1.28*10-2, Beta=-0.398). 176 
 177 
Gene expression analyses 178 
In order to identify potential causal genes located in the LD block surrounding rs4764133, we assessed 179 
gene expression of MGP, ERP27, ART4, SMOC3 (C12orf69) and C12orf60 in articular cartilage, the 180 
primary OA affected tissue. RNA sequencing was obtained on articular cartilage from primary OA 181 
patients who had total joint replacement surgeries of either the knee (n=25) or hip (n=22) joint. 182 
Expression levels of ERP27,C12orf60,ART4 and SMOC3  were substantially lower than MGP expression 183 
levels in articular cartilage (Figure. S2A). Nonetheless, neither MGP, ERP27, ART4 nor SMOC3 and 184 
C12orf60 showed significant difference in gene expression between paired preserved(P) and OA 185 
lesioned(OAL) articular cartilage. However, while these genes are not differentially expressed in OA 186 
affected cartilage, it is possible that the identified GWAS SNPs affect gene transcription. When we 187 
analysed the relationship between the top SNP and expression analysis in a classical eQTL (expression 188 
Quantitative Trait Loci) analysis, we did not to detect significant correlations between rs1049897, rs4236 189 
or rs1800801 and absolute MGP, ERP27, ART4, SMOC3 or C12orf60 expression levels (Figure S2B). 190 
However, we did observe several variants in high LD located in the mRNA transcript of MGP and 191 
C12orf60, allowing us to assess allele specific expression (ASE) for these genes. We were unable to study 192 
ASE for ART4, SMOC3 and ERP27, since no SNP in high LD with rs4764133 is present in the coding region.  193 
In ASE the influence of exonic alleles on gene expression in-cis is measured within heterozygote 194 
subjects, circumventing strong effects from environmental or trans-acting influences. This property 195 
results in ASE analysis to be a more statistically powerful approach, when compared to classical eQTL 196 
analysis [28]. Subsequently, we found that the OA risk alleles for three coding variants in high LD with 197 
the lead variant, rs4236 (Figure. 3SA, 39.6% C allele, P<5*10-16), rs1049897 (Figure. S3B, 44.4% A allele, 198 
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P<5*10-10), and rs1800801 (Figure. 3A, 40.7% T allele, P<5*10-16), were significantly correlated with 199 
lower expression of MGP, marking imbalanced expression among heterozygotes, independent of the 200 
disease status of the articular cartilage. No allele specific expression was observed between SNPs 201 
rs11276, rs3088189 and rs1861698  (residing in C12orf60 and in high LD with the lead SNP,r2>0.8, Table 202 
2). Technical and biological replication was performed using a custom allele specific TaqMan assay for 203 
rs1800801 in eight additional heterozygous individuals for which we isolated RNA from P cartilage (n=2), 204 
OAL (n=2) or both (n=4) from primary knee OA patients and confirmed the observed imbalance in 205 
preserved articular cartilage (Figure 3B, relative allelic difference=0.92, P<1*10-6), as well as in 8 knee 206 
subchondral bone samples (Figure 3C, relative allelic difference=0.78, P<1*10-4).   207 
 208 
Discussion 209 
Here, we show for the first time, that there is a robust genome-wide significant association between 210 
rs4764133, located near MGP, and hand OA. Furthermore we performed functional validation showing 211 
that MGP coding variants in LD with rs4764133 are associated with allele-specific expression of MGP 212 
which may increase risk of hand OA by lowering inhibition of articular cartilage calcification, since MGP 213 
is an essential inhibitor of cartilage calcification[29,30]. These findings suggest that MGP could be 214 
considered a prioritized drug target for hand OA, since genetically supported drug targets double the 215 
success rate of therapeutics in clinical development[31]. 216 
 MGP is an essential inhibitor of cartilage calcification, and genetic deficiencies of MGP in 217 
humans and mice have been linked to abnormal mineralization of soft tissues, including cartilaginous 218 
tissue[29,32]. Furthermore MGP has been previously implicated in relation to OA. A small candidate 219 
study reported marginally significant association between hand OA and genetic variants in MGP 220 
(rs1800802 and rs4236)[33]. This is consistent with our findings that the minor allele for rs4764133 and 221 
related coding variants in high LD (r2>0.8), rs1800802 and rs4236, increase the risk of hand OA and that 222 
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we found high expression of MGP in both preserved and OA lesioned articular cartilage. In contrast, 223 
another study showed that an MGP protein complex is excreted by healthy articular chondrocytes, but 224 
not by OA affected chondrocytes[34], although we only assed MGP expression and not MGP protein 225 
complex excretion.  226 
Although the loci with allele specific expression (ASE) are known to be enriched for eQTLs[35], 227 
we were unable to detect an association between the MGP-genotype and MGP RNA-expression levels in 228 
cartilage. This could have been due to our modest sample size (knee joint, n=25 and or hip joint, n=22) in 229 
combination with large heterogeneity of the tissue. Notably, the available cartilage samples originated 230 
from different joint sites (knee, hip) and different disease stage (preserved versus affected), and had 231 
large age range of the individuals. Also, It is known that ASE is a more powerful technique then classical 232 
eQTL analysis to identify functional SNPs influencing expression of genes[28]. While the extent of 233 
imbalance could be considered relatively modest, an increasing number of OA associated SNP alleles 234 
appear to mark ASE by comparable amount[19,36–38]. From a more biological perspective, one could 235 
consider a prolonged, albeit slight, deviation from homeostasis due to modest ASE of cartilage relevant 236 
genes to be of substantial influence over time. This latter hypothesis could contain the molecular basis 237 
for increased risk towards developing OA among the ageing population. Additionally, we observed that 238 
the rs1800801 alleles also affected expression of MGP  in subchondral bone samples. This could imply 239 
that, in parallel to an effect in cartilage, he presumed disturbed cartilage homeostasis is further affected 240 
by the underlying bone. Further enabling the view that OA is a pathology of the entire joint. 241 
Our findings may give an explanation for the known vitamin K association with OA: MGP 242 
mediated calcification inhibition is dependent on γ-carboxylation by vitamin K[39]. It has been shown 243 
that low vitamin K intake is correlated with OA[40]. Thus vitamin K intake may be a potential therapeutic 244 
treatment in OA. Recently, a first randomized control trial testing the effects of vitamin K on OA was 245 
published, which reported no overall effect of vitamin K on hand OA[41]. Despite the low power of the 246 
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trial, there was a significant beneficial effect on joint space narrowing (cartilage degradation) among 247 
those individuals that were VitK deficient at the start of the trial[41]. Thus, an adequately powered study 248 
of vitamin K may be justified based on the found MGP association. Furthermore, genetic predisposition 249 
for hand OA, was not taken into account in the trial. Perhaps, genetic predisposition for hand OA (MGP-250 
risk variants) in combination with insufficient vitamin K intake might potentiate cartilage calcification 251 
and subsequent risk for developing hand OA. Therefore, future OA trails, therapeutic and preventive 252 
treatments might benefit from taking a personalized medicine approach since genetically supported 253 
drug targets double the success rate of therapeutics in clinical development[31]. 254 
Styrkarsdottir et al.(2014) reported on common genetic variants that associate with severe hand 255 
OA, among the replication cohorts were the Leiden and Rotterdam cohorts[19]. Although we observe 256 
suggestive signals at the reported locus (ALDH1A2 gene,  1p31) the respective variants did not meet the 257 
genome-wide significance threshold in our analyses (Supplementary Table S5). This difference is likely 258 
caused by the markedly different phenotypes that were used for either analyses. Where Styrkarsdottir 259 
et al. studied a dichotomous severe hand OA phenotype, our phenotype was semi-quantitatively 260 
phenotype.  261 
To conclude, we here present coding variants in MGP, that are associated with radiographic 262 
hand OA, and the hand OA risk allele marks lower expression of MGP in articular cartilage. Our findings 263 
suggest that MGP might play an important role in hand OA pathogenesis through pathways related to 264 
articular cartilage calcification and vitamin K. Better understanding of MGP gene and protein regulation 265 
and its relation to vitamin K intake and OA, may reveal novel therapeutic drug targets for hand OA.    266 
 267 
  268 
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Figures 432 
Figure 1. GWAS results for association with the KLsum score in the discovery phase. Manhattan plot for association 433 
with the KLsum-score, adjusted for age and sex, in the discovery cohorts of RSI, RSII and RSIII. The -log10 P-values, 434 
for each of the ~11 million SNPs analyzed (remaining after EASYQC quality control) as part of the genome wide 435 
association with the KLsum-score, plotted against their position per chromosome. The red dotted horizontal line 436 
corresponds to the genome-wide significant threshold (P = 5x10-8). The dotted grey line corresponds to the 437 
selection for replication threshold (P = 5x10-6). SNP location represented by [], if the SNP is localized intergenic the 438 
dashes denotes the distance, -≤10 kb, --≤100kb, ---≤1000kb, ----≤1Mkb, -----≥1Mkb. 439 
 440 
Figure 2. Locus zoom plot for rs4764133. locus zoom plot for rs4764133, 150 kb upstream and downstream of 441 
rs4764133 has been taken as plotted region (A). Zoom in on MGP and three SNPs in high LD with top SNP that are 442 
located in the MGP mRNA transcript (B). Also represented is ROADMAP chromatin 18-state data of two tissue 443 
types: human Mesenchymal Stem Cell (hMSC) derived cultured chondrogenic cells and primary osteoblasts. In 444 
both these cell types the chromatin contains active marks surrounding the MGP  promoter.   445 
 446 
Figure 3. Allelic imbalanced expression of MGP marked by the alleles among heterozygotes of rs1800801 (A), in 447 
the assessed cartilage RNA sequencing dataset. Validation of selected rs1800801 using a custom TaqMan assay 448 
confirmed the imbalance (B). Allelic imbalance was also assed in with a custom TagMan assay in subchondral bone 449 
samples (C). Preserved (P) and OA lesioned (OAL) samples are shown respectively in blue and red, and genomic 450 
DNA (TaqMan control) in black (G).  For ASE results for rs4236 and rs1049879, see Supplementary Figure S3 and for 451 
information on the samples see Supplementary Table S2.  452 
  453 
  454 
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Table 1. Results GWAS quantitative bilateral phenotype of osteoarthritis of the hand (KLsum-score), discovery, replication and meta-analysis 455 
      
Discovery* Replication** Combined 
 
SNP Chr 
Position 
(hg19) 
Effect 
Allele 
Other 
Allele 
EAF† Beta SE P-value Beta SE P-value Beta SE Pval 
Genomic 
location†† 
rs1494593 5 23574856 T C 0.88 -0.83 0.18 4.46E-06 -0.15 0.32 6.31E-01 -0.67 0.16 2.28E-05 PRDM9--[]---C5orf17 
rs114370021 5 167398535 A G 0.27 -0.84 0.18 2.12E-06 0.48 0.32 1.28E-01 -0.53 0.16 6.96E-04 [TENM2] 
rs7770034 6 44447004 A G 0.48 -0.54 0.12 3.42E-06 -0.36 0.21 8.71E-02 -0.50 0.10 1.01E-06 CDC5L --[]---SUPT3H 
6:132063842:D‡ 6 132063842 D I 0.27 0.64 0.13 1.28E-06 0.41 0.23 7.82E-02 0.58 0.11 3.79E-07 [ENPP3] 
11:90657297:D 11 90657297 D I 0.11 0.93 0.19 1.35E-06 0.33 0.33 3.11E-01 0.78 0.17 2.91E-06 DISC1FP1-[]----FAT3 
rs4764133 12 15064363 T C 0.39 0.75 0.12 3.45E-10 1.11 0.22 3.34E-07 0.83 0.10 1.80E-15 MGP--[]- ERP27 
rs7139060 12 28693144 A G 0.67 -0.73 0.12 6.12E-09 0.11 0.22 6.16E-01 -0.52 0.11 1.47E-06 [CCDC91] 
rs1950427 14 25955502 T C 0.12 0.86 0.18 1.09E-06 -0.28 0.30 3.56E-01 0.57 0.15 1.80E-04 STXBP6---[]---NOVA1 
rs6108226 20 8960884 T C 0.77 0.70 0.15 3.94E-06 0.20 0.27 4.43E-01 0.58 0.13 1.14E-05 PLCB1--[]--PLCB4 
* Discovery: RS-I, RS-II, RS-III, n= 8,743  
            ** Replication : GARP, LSS, TwinsUK & FHS, n= 4,011   
           † EAF: Effect Allele Frequency 
 
      ††SNP location represented by [], if the SNP is localized intergenic the dashes denotes the distance, -≤10 kb, --≤100kb, ---≤1000kb, ----≤1Mkb, -----≥1Mkb 
‡For TwinsUK a proxy SNP was used: rs3850251 r2=1 D'=1 (as calculated in the RSI, RSII and RSIII cohorts) 
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Table 2. rs4764133 LD block (r²>0.8) annotation of potential functional elements in osteoblasts and 456 
chondrogenic cells, X marks no potential functional annotation i.e. enhancer region, promoter region or 457 
altered protein binding motifs. 458 
    
Regulatory Chromatin Marks** 
 
SNP 
P-value 
Discovery r² Annotation* 
Chondrogenic 
cells Osteoblasts 
Altered Protein 
Binding Motifs 
(Haploreg V3) 
rs1049897 3.48E-09 0.88 MGP 3'-UTR Transcription X X 
rs4236 4.16E-09 0.86 MGP non-
synonymous 
Enhancer region X HNF4, PLAG1 
rs1800801 1.12E-09 0.95 MGP 5'UTR Promoter region Promoter region Zfp410 
rs7310951 4.04E-09 0.86 C12orf60 Enhancer region X DMRT7, Gfi1, Pax-5 
rs12320004 4.04E-09 0.86 C12orf60 Enhancer region X BHLHE40, P300, HEN1, 
LBP-1, RAD21,TATA, 
Zfx 
rs10772814 3.76E-09 0.88 C12orf60 Enhancer region X HNF4 
rs10492151 1.21E-09 0.95 C12orf60 Enhancer region X AIRE, Hoxa13 
rs725445 3.58E-08 0.82 C12orf60 Enhancer region X Hand1 
rs725444 3.92E-09 0.87 C12orf60 Enhancer region X Foxf1, Foxi1, Foxo, 
Foxq1, Mef2 
rs4764131 6.31E-10 0.97 C12orf60 Enhancer region Enhancer region Myc 
rs9668569 5.91E-10 0.97 C12orf60 Promoter region Promoter region X 
rs2430687 2.44E-09 0.89 C12orf60 Enhancer region Enhancer region BHLHE40 
rs12311463 6.91E-10 0.97 C12orf60 Enhancer region Enhancer region Pou1f1, Pou2f2, TATA 
rs67482087 4.61E-10 0.95 C12orf60 Enhancer region Enhancer region Foxp1, Irx, Pou1f1, 
Pou2f2, Pou3f3, TATA 
rs67436073 6.76E-10 0.97 C12orf60 Enhancer region Enhancer region Foxj2, Foxk1, Foxo, 
GATA, Mef2, Pou2f2, 
Pou3f2, Pou6f1, TATA, 
Zfp 
rs11276 8.05E-09 0.96 C12orf60 non-
synonymous 
X X SPIB,NF-AT 
rs3088189 9.46E-09 0.96 C12orf60 
synonymous 
X X SPIB 
rs1861698 3.56E-09 0.96 C12orf60 
synonymous 
X X Bbx, Pou1f1, TATA 
*Gene annotation based on the hg19 release of the UCSC Genome Browser 
  ** Regulatory chromatin marks taken from the ROADMAP Epigenomes project chromatin state learning core 18-state 
model 
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